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Turmeric for Prevention of Dementia:
Food for Thought
Mustafa M. Husain, M.D., Yamna Channa, M.B.B.S., Mohan Chilukuri, M.D.
Let thy food be thy medicine, and let thy medicine be thy food.
—Hippocrates.

he understanding of neurodegenerative disorders
has increased a great deal in the last few decades.
Our understanding of the causes, types, and pathophysiology of dementia has increased immensely—but
we are still a long way off from preventing or finding
treatments for these disorders.
The anti-inflammatory effects of the active compound in the bright yellow South Asian spice turmeric
have been documented as early as 1973.1 Turmeric has
been considered an effective herbal remedy for many
health problems, including mental health problems, and
is firmly entrenched among the traditional herbal cures
in the Indo-Pak subcontinent. It is a component of
widely used herbal treatment for cold, catarrh, and
cough.2 Recent research indicates that the active compound of turmeric, curcumin, may have uses that
extend well beyond that of a spice used to flavor food.3
Previous research into the effect of turmeric on Alzheimer disease (AD) indicates that it has antioxidant
activity and that it inhibits amyloid beta aggregation.
These studies recommend further research into the
impact of curcumin on dementia.4 Earlier research
has shown that patients develop predictable changes
in brain pathology before symptoms of AD develop.
It is also known that tau pathology leads to cognitive
deficits in Alzheimer dementia.5 Previous research
recommended that any future research into the
role of curcumin on cognition include measures of
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cognitive outcome in conjunction with biological
markers of neurodegeneration.6 Small et al.7 fulfill that
recommendation.
In this issue of The American Journal of Geriatric Psychiatry, Small et al.7 examine the relationship between
the use of a highly bioavailable form of curcumin
(Theracurmin) and its effects on memory and neuropathological markers. Forty subjects were recruited for
this trial; 21 of these received Theracurmin and the remaining subjects received a placebo. The study subjects
were screened at baseline for any comorbidity that could
interfere with study results. For example, all subjects
were screened for major depressive disorder, which
can cause pseudo-dementia and thus decrease cognition.
Small et al. recognized the need for a study that
would monitor the effect of curcumin on long-term
memory and cognition. The period of 18 months was
chosen based on the results of previous trials suggesting that this is the optimum time period to monitor
long-term effects of curcumin. This placebo-controlled
trial recruited individuals without dementia and those
with mild cognitive impairment. People with dementia were excluded from the study as the aim was to
study the role of curcumin as a prophylactic agent
rather than as a treatment or cure for dementia.
Change in memory of study subjects was measured using the Buschke SRT and the Consistent Long
Term Retrieval Scores. Changes in biomarkers (i.e., accumulation of amyloid and tau plaques) were
monitored via 2-(1-{6-[(2-[F-18] fluoroethyl) (methyl)
amino]-2-naphthyl} ethylidene) malononitrile positron emission tomography (FDDNP-PET). Buschke SRT
is a sensitive test that can predict future cognitive
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decline. As well as following study subjects for 18
months, Small et al. also used tools that predict future
cognitive decline. This allows for accurate interpretation of the long term effects of Theracurmin.
The group using Theracurmin showed improved
memory as measured by the Buscke SRT and the Consistent Long Term Retrieval Scores. This group was also
found to have decreased FDDNP binding in the amygdala and hippocampus. Thus, the results indicate that
Theracurmin improves memory and cognition. The
results of this trial by Small et al. also indicate that
curcumin decreases the neuropathological accumulation of tau and amyloid proteins in the amygdala and
hypothalamus—a finding that is correlated with
dementia.
What is the impact of this study on the current treatment, management, and prevention of dementia?
Dementia is a poorly understood disease and there
is little evidence supporting definitive cure, treatment,
or prevention. This study is based on previously conducted experiments that provide indication for the use
of curcumin in disintegrating tau filaments and amyloid
plaques.8
Small et al.’s investigation is an important and novel
study that opens doors for future targeted intervention in the field of dementia treatment and prevention
research. Theracurmin is a natural herbal compound

and is considered safe compared to other pharmacological agents that are standard of care for dementia
currently. The side effects reported in this trial by Small
et al. involve mild gastrointestinal side effects. No subjects reported side effects severe enough to require
discontinuation of Theracurmin. For any patient population this is an important aspect to consider, but more
so in patients suffering from dementia. These patients are older and are often victims of the negative
effects of polypharmacy. Therefore the fact that
Theracurmin has few side effects is an important advantage. It would also be relevant for future research
to monitor possible drug interactions of Theracurmin
with other medications that are commonly used in the
elderly patient population.
Future studies may also clarify if the effect of
Theracurmin to delay the onset of dementia or to
prevent it. This is an important consideration, as
Theracurmin may have the potential to significantly
decrease the incidence and prevalence of this debilitating illness.
Small et al.’s findings also bolster the results of previous research that indicates an improvement in mood
and anxiety symptoms with the use of curcumin. It
would be an interesting area for future research to
develop a trial focused on illuminating further this
aspect of the effects of curcumin.
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